Home
Finance & valuation

Finance & valuation

Five key patent transactions takeaways

An over-arching theme during an IAM event was the key importance of relationships, trust and empathy between parties when deals are getting done

WiLAN revenues plummet in Q3 on prior year but Micron deal excluded

Strategic review of the licensing business nears a year in motion with no news on potential divestment announced

Drug royalty agreements can help Big Pharma overcome patent cliffs, says top dealmaker

Behzad Khosrowshahi, CEO of DRI Healthcare Trust, looks at recent deals the firm has done, explains what makes a transaction attractive and how to get one over the line

Latest content

Pfizer’s $2.3 billion spend on CD47 inhibitors shows how oncology IP continues to drive pharma deal-making

The acquisition of the cutting-edge haematology candidates is just the latest development in the booming immuno-oncology market

26 August 2021

Toyota’s self-driving haul from Lyft includes 100+ US patent assets

Patents change hands after Japanese carmaker buys Lyft’s self-driving tech for $550 million

23 August 2021

Japan’s corporate watchdog calls for high-level emphasis on intellectual property

Changes to the country’s corporate governance code encourage boards to pay more attention to IP strategy

18 August 2021

mRNA IP will be hot property beyond the pandemic

$3.2 billion Sanofi deal is unlikely to be the last as Big Pharma seeks to consolidate its position in the cutting-edge field

12 August 2021

FC Barcelona faces possible €137 million drop in brand value in wake of Messi’s departure

The Argentine superstar is also IP-savvy, with a trademark portfolio far bigger than any of his rivals for the crown of the world's best footballer

10 August 2021

Healthcare Royalty Partners’ $750 million IPO to be next milestone for a booming market

The company is hoping to raise cash to help expand its purchasing power when acquiring pharmaceuticals revenue streams

05 August 2021

Investor interest in IP is about more than big money verdicts, claims Ocean Tomo transactions chief

Ten-figure awards in the patent space have caught capital’s attention, says Ocean Tomo's Ryan Zurek, but so has the IP market’s resilience in the face of economic turbulence

04 August 2021

Biopharma M&A has fallen off a cliff – but IP owners in the sector have reasons to be cheerful

The number and value of acquisitions have both tumbled further than in the early months of 2020

20 July 2021

Singapore banking on regional IP rise and dispute resolution to cement its hub status

An update to the country’s strategy recognises that facilitating ASEAN's patenting development is key

19 July 2021

IAM insight panel analysis Q2 2021

Featured in Community Insight

Second quarter panels report finds a marked increase in negative views about the administration, but fewer covid concerns and signs of higher royalty and sales prices

01 July 2021

Unlock unlimited access to all IAM content